Biocon Refutes Graft Charges After Regulatory Official Booked, Says Due Process Followed
Expert Panel Trial Waiver Endorsement Came In May
Indian investigating agency probes alleged bribe paid to drugs regulator in a case pertaining to the approval process of Biocon Biologics’ insulin aspart. The company strongly denies the allegations, underscoring that all its product approvals are backed by science and clinical data.
